BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 16883013)

  • 1. The role of PET in lymphoma.
    Jhanwar YS; Straus DJ
    J Nucl Med; 2006 Aug; 47(8):1326-34. PubMed ID: 16883013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
    Qiu L; Chen Y; Wu J
    Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG-PET in the clinical management of Hodgkin lymphoma.
    Hutchings M; Eigtved AI; Specht L
    Crit Rev Oncol Hematol; 2004 Oct; 52(1):19-32. PubMed ID: 15363464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma.
    Hutchings M; Loft A; Hansen M; Pedersen LM; Berthelsen AK; Keiding S; D'Amore F; Boesen AM; Roemer L; Specht L
    Haematologica; 2006 Apr; 91(4):482-9. PubMed ID: 16585015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The value of integrated PET-CT images in 2 lymphoma patients with skeletal localisations].
    Geerts MC; Quarles van Ufford HM; Kramer MH; van Waes PF; de Klerk JM
    Ned Tijdschr Geneeskd; 2006 Jan; 150(4):204-9. PubMed ID: 16471237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
    Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O
    Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
    Kasamon YL; Jones RJ; Wahl RL
    J Nucl Med; 2007 Jan; 48 Suppl 1():19S-27S. PubMed ID: 17204717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET/CT for the staging and follow-up of patients with malignancies.
    Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
    Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance imaging of malignant lymphoma.
    Vermoolen MA; Kersten MJ; Fijnheer R; van Leeuwen MS; Kwee TC; Nievelstein RA
    Expert Rev Hematol; 2011 Apr; 4(2):161-71. PubMed ID: 21495926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
    Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of FDG-PET/CT in the management of lymphoma.
    Baba S; Abe K; Isoda T; Maruoka Y; Sasaki M; Honda H
    Ann Nucl Med; 2011 Dec; 25(10):701-16. PubMed ID: 22037934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-induced pneumonitis detected earlier by 18F-FDG-PET than by high-resolution CT: a case report with non-Hodgkin's lymphoma.
    Yamane T; Daimaru O; Ito S; Nagata T; Yoshiya K; Fukaya N; Ito S; Imai T; Uchida H
    Ann Nucl Med; 2008 Oct; 22(8):719-22. PubMed ID: 18982476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT compared to standard contrast-enhanced CT for characterization and staging of pulmonary tumors eligible for surgical resection.
    Quaia E; Tona G; Gelain F; Lubin E; Pizzolato R; Boscolo E; Bussoli L
    Acta Radiol; 2008 Nov; 49(9):995-1004. PubMed ID: 18651256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrepancies and priorities in staging and restaging malignant lymphoma by SPET, SPET/CT, PET/CT and PET/MRI.
    Chavdarova LI; Tzonevska AD; Piperkova EN
    Hell J Nucl Med; 2013; 16(3):223-9. PubMed ID: 24137584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of advanced non-Hodgkin's lymphoma involving the prostate: staging and treatment monitoring using F-18 FDG PET/CT imaging.
    Cimarelli S; Lachenal F; Ricard F; Chassagne-Clément C; Heudel PE; Janody P; Sebban C
    Clin Nucl Med; 2010 Jun; 35(6):425-7. PubMed ID: 20479591
    [No Abstract]   [Full Text] [Related]  

  • 16. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
    Castellucci P; Perrone AM; Picchio M; Ghi T; Farsad M; Nanni C; Messa C; Meriggiola MC; Pelusi G; Al-Nahhas A; Rubello D; Fazio F; Fanti S
    Nucl Med Commun; 2007 Aug; 28(8):589-95. PubMed ID: 17625380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of functional imaging in the management of lymphoma.
    Cheson BD
    J Clin Oncol; 2011 May; 29(14):1844-54. PubMed ID: 21482982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET/CT for therapy response assessment in lymphoma.
    Hutchings M; Barrington SF
    J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients.
    Saif MW; Cornfeld D; Modarresifar H; Ojha B
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):173-8. PubMed ID: 18568138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
    Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
    J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.